We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.21%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.06B
AUM Growth
-$395M
Cap. Flow
-$256M
Cap. Flow %
-5.05%
Top 10 Hldgs %
43.96%
Holding
127
New
13
Increased
22
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
ITGR icon
Integer Holdings
ITGR
+$40.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$39.5M
3
EXAS
Exact Sciences
EXAS
+$29.3M
4
ARGX icon
argenx
ARGX
+$22M
5
AMGN icon
Amgen
AMGN
+$21M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$106M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
3
JANX icon
Janux Therapeutics
JANX
+$60.8M
4
ESPR
Esperion Therapeutics
ESPR
+$36.7M
5
SRRK icon
Scholar Rock
SRRK
+$30.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNTE
126
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-8,009,729
Closed -$21.3M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2024 Portfolio in Review

As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed withdrew a net $256M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.

  • OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
  • OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
  • OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
  • OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
  • OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
  • OrbiMed opened 13 new positions and closed 13 in Q2 2024.
  • OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.